Compare JetBlue Airways Corporation (JBLU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? JetBlue Airways Corporation trades at $3.03 (market cap $1.26B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3.9× JetBlue Airways Corporation's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| JBLU | TVTX | |
|---|---|---|
Market Cap | $1.26B | $4.88B |
Volume | 40,642,525 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $6.46 | $67.52 |
52-Week Low | $3.01 | $26.79 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $8.63B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.01, down 16.85% in the last 24 hours, reflecting significant bearish pressure. The stock exhibits weak fundamentals with a negative net income margin of -9.32% and consecutive quarterly losses, though it beat EPS expectations in Q2 2026. Technical indicators are predominantly bearish, with the stock trading near key support levels. Recent news highlights expansion efforts like new routes to Colombia and the launch of BlueFirst premium seating, aiming to boost revenue amid industry challenges.
The outlook remains challenging due to persistent losses, high debt levels, and elevated fuel costs. While analyst consensus suggests a hold rating with a $5.89 price target implying potential upside, risks from competitive pressures and macroeconomic factors dominate. Investment appeal is limited to speculative positions betting on a operational turnaround despite current headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
